Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tumor-Agnostic First In England As NICE Reverses Vitrakvi Rejection

Executive Summary

Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.

You may also be interested in...

Roche Wins Funding For Second Histology-Independent Drug In England

Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.

English Funding Success For Roche’s Rozlytrek In NSCLC

English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts